A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting

British Journal of Haematology
Markus KüglerGeorg H Fey

Abstract

Two trivalent constructs consisting of single-chain Fv antibody fragments (scFvs) specific for the interleukin-3 receptor alpha chain (CD123), CD33 and the Fcgamma-receptor III (CD16) were designed and characterized for the elimination of acute myeloid leukaemia (AML) cells. The dual targeting single-chain Fv triplebody (sctb) [123 x ds16 x 33] and the mono targeting sctb [123 x ds16 x 123] both specifically bound their respective target antigens and were stable in human serum at 37 degrees C for at least 5 d. Both constructs induced potent antibody-dependent cellular cytotoxicity (ADCC) of two different AML-derived CD33- and CD123 double-positive cell lines in the low picomolar range using isolated mononuclear cells (MNCs) as effector cells. In these experiments the dual targeting molecule produced significantly stronger lysis than the mono targeting agent. In addition, the sctbs showed a high potency in mediating ADCC of primary leukaemia cells isolated from peripheral blood or bone marrow of seven AML patients. Hence, these novel molecules displayed potent anti-leukaemic effects against AML cells in vitro and represent attractive candidates for further preclinical development.

References

May 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·H B FleitJ C Unkeless
Jan 1, 1997·Annual Review of Immunology·M Daëron
Jun 1, 1997·Immunotechnology : an International Journal of Immunological Engineering·A Plückthun, P Pack
Oct 8, 1999·Journal of Molecular Biology·S M KipriyanovM Little
Nov 25, 2003·Hematology·Bob LöwenbergMartin S Tallman
Dec 13, 2003·Leukemia·U TestaC Peschle
May 18, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniel A ValleraHua Chen
Sep 17, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anna van RhenenGerrit Jan Schuurhuis
Oct 7, 2005·Critical Reviews in Oncology/hematology·W HiddemannUNKNOWN German AML Cooperative Group
Jan 24, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Farhad Ravandi, Zeev Estrov
Apr 14, 2006·British Journal of Haematology·Michael SchwemmleinGeorg H Fey
Apr 20, 2006·Nature Reviews. Immunology·Paul J Carter
Sep 26, 2006·Nature Medicine·Liqing JinJohn E Dick
Nov 28, 2006·Lancet·Elihu Estey, Hartmut Döhner
Dec 22, 2006·European Journal of Clinical Investigation·A W HauswirthP Valent
Jun 20, 2007·Proceedings of the National Academy of Sciences of the United States of America·Naoki HosenIrving L Weissman
Oct 24, 2007·Nature Biotechnology·Fumihiko IshikawaLeonard D Shultz
Mar 21, 2008·Expert Opinion on Biological Therapy·Roberto Stasi
Dec 10, 2008·Blood·John E Dick

❮ Previous
Next ❯

Citations

May 3, 2011·The Journal of Biological Chemistry·Achim BoltzBjoern Hock
Jun 29, 2012·Protein Engineering, Design & Selection : PEDS·Shu-Ru KuoJen-Sing Liu
May 9, 2014·Blood Reviews·George S LaszloRoland B Walter
Apr 26, 2014·Immunotherapy·Cord Naujokat
Mar 19, 2014·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Ron D JachimowiczAchim Rothe
Jan 3, 2013·Cytometry. Part B, Clinical Cytometry·Daniela S KrauseFrederic I Preffer
Dec 11, 2013·British Journal of Haematology·Robin E GasiorowskiDerek N J Hart
Dec 21, 2014·International Immunopharmacology·Liming XuDeshan Li
Jun 2, 2015·Pharmaceutical Patent Analyst·Gillian A HorneMhairi Copland
May 17, 2015·Cellular Immunology·Hans-Heinrich ObergDaniela Wesch
Apr 22, 2015·Current Hematologic Malignancy Reports·Sarah A Buckley, Roland B Walter
Mar 29, 2012·MAbs·Roland E Kontermann
Nov 26, 2013·Trends in Molecular Medicine·Maulik VyasElke Pogge von Strandmann
Dec 3, 2014·Seminars in Oncology·Darshil T JhaveriElizabeth M Jaffee
Dec 3, 2014·Life Sciences·Keqiang LiuYechen Xiao
Feb 12, 2014·Biomarker Research·Ugo TestaArthur Frankel
May 10, 2016·Analytical Biochemistry·Shima Moradi-KalbolandiMohammad Ali Shokrgozar
Aug 30, 2016·The Journal of Clinical Investigation·Marco RuellaSaar Gill
Oct 21, 2016·Computational and Structural Biotechnology Journal·Marco Ruella, Marcela V Maus
Jan 11, 2017·MAbs·Ulrich Brinkmann, Roland E Kontermann
Mar 10, 2016·The Analyst·Elisavet I ChatzopoulouJoachim O Rädler
Oct 6, 2017·Protein Engineering, Design & Selection : PEDS·Thorsten GantkeMartin Treder
Sep 27, 2014·World Journal of Stem Cells·Jianbiao Zhou, Wee-Joo Chng
Jan 11, 2019·Leukemia & Lymphoma·Hongbing MaYuping Gong
Jun 9, 2019·Nature Reviews. Drug Discovery·Aran F LabrijnPaul W H I Parren
Nov 10, 2017·Blood·Mireya Paulina VelasquezStephen Gottschalk
Aug 11, 2019·Current Pharmaceutical Biotechnology·Miriam DiboLígia C Faccin-Galhardi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.